Pyrimidine: a review on anticancer activity with key emphasis on SAR
A Mahapatra, T Prasad, T Sharma - Future journal of pharmaceutical …, 2021 - Springer
Background Cancer is a global health challenge, it impacts the quality of life and its
treatment is associated with several side effects. Resistance of the cancer cells to the …
treatment is associated with several side effects. Resistance of the cancer cells to the …
Recent developments in anticancer kinase inhibitors based on the pyrazolo [3, 4-d] pyrimidine scaffold
DJ Baillache, A Unciti-Broceta - RSC medicinal chemistry, 2020 - pubs.rsc.org
Pyrazolo [3, 4-d] pyrimidines have become of significant interest for the medicinal chemistry
community as a privileged scaffold for the development of kinase inhibitors to treat a range …
community as a privileged scaffold for the development of kinase inhibitors to treat a range …
Synthesis of 4, 6-disubstituted pyrazolo [3, 4-d] pyrimidine analogues: Cyclin-dependent kinase 2 (CDK2) inhibition, molecular docking and anticancer evaluation
S Cherukupalli, B Chandrasekaran, RR Aleti… - Journal of Molecular …, 2019 - Elsevier
The cyclin-dependent kinases (CDKs) play a crucial role in cell cycle progression and are
validated targets of cancer therapy. Pyrazolopyrimidines are versatile scaffolds, which have …
validated targets of cancer therapy. Pyrazolopyrimidines are versatile scaffolds, which have …
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor
AL Fallacara, C Zamperini, A Podolski-Renić, J Dinić… - Cancers, 2019 - mdpi.com
Overexpression of P-glycoprotein (P-gp) and other ATP-binding cassette (ABC) transporters
in multidrug resistant (MDR) cancer cells is responsible for the reduction of intracellular drug …
in multidrug resistant (MDR) cancer cells is responsible for the reduction of intracellular drug …
Novel pyrazolo [3, 4-d] pyrimidines as dual Src/Bcr-Abl kinase inhibitors: synthesis and biological evaluation for chronic myeloid leukemia treatment
S Di Maria, F Picarazzi, M Mori, A Cianciusi… - Bioorganic …, 2022 - Elsevier
Abstract The Bcr-Abl tyrosine kinase (TK) is the molecular hallmark of chronic myeloid
leukemia (CML). Src is another TK kinase whose involvement in CML was widely …
leukemia (CML). Src is another TK kinase whose involvement in CML was widely …
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-d]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against …
F Poggialini, C Vagaggini, A Brai, C Pasqualini… - Pharmaceutics, 2023 - mdpi.com
The therapeutic use of tyrosine kinase inhibitors (TKIs) represents one of the successful
strategies for the treatment of glioblastoma (GBM). Pyrazolo [3, 4-d] pyrimidines have …
strategies for the treatment of glioblastoma (GBM). Pyrazolo [3, 4-d] pyrimidines have …
A comprehensive review on the indazole based derivatives as targeted anticancer agents
S Puri, S Sawant, K Juvale - Journal of Molecular Structure, 2023 - Elsevier
Cancer is one of the leading causes of death worldwide, resulting in the deaths of millions of
individuals. Owing to the development of drug resistance to conventional therapies …
individuals. Owing to the development of drug resistance to conventional therapies …
Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model
G Vignaroli, G Iovenitti, C Zamperini… - Journal of Medicinal …, 2017 - ACS Publications
Pyrazolo [3, 4-d] pyrimidines are potent protein kinase inhibitors with promising antitumor
activity but suboptimal aqueous solubility, consequently worth being further optimized …
activity but suboptimal aqueous solubility, consequently worth being further optimized …
Development of Pyrazolo[3,4-d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor. Residual cells at
the tumor margin are responsible for up to 85% of GBM recurrences after standard …
the tumor margin are responsible for up to 85% of GBM recurrences after standard …
Studies on the ATP binding site of Fyn kinase for the identification of new inhibitors and their evaluation as potential agents against tauopathies and tumors
Fyn is a member of the Src-family of nonreceptor protein–tyrosine kinases. Its abnormal
activity has been shown to be related to various human cancers as well as to severe …
activity has been shown to be related to various human cancers as well as to severe …